drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Subcutaneous CD20xCD3 bispecific T-cell–engaging antibody that redirects patient T cells via CD3 to lyse CD20-positive B-cell lymphoma; administered with step-up dosing.
nci_thesaurus_concept_id
C129691
nci_thesaurus_preferred_term
Mosunetuzumab
nci_thesaurus_definition
A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Mosunetuzumab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, mosunetuzumab binds to both T-cells and CD20-expressing tumor B-cells; this cross-links T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Humanized CD20×CD3 bispecific antibody that binds CD20 on B cells and CD3 on T cells, crosslinking them to form an immune synapse and activate T-cell cytotoxicity to lyse CD20-positive malignant B cells.
drug_name
Mosunetuzumab
nct_id_drug_ref
NCT05994235